CTIS2022-501325-20-00进行中（未招募）1 期
BLCL-NIL-PIL03
Bluepharma Industria Farmaceutica S.A.0 个研究点目标入组 20 人开始时间: 2022年7月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditionso medical condition.CTIS2023-509808-15-00Pharmaplot P.C.12
进行中（未招募）
1 期
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy SubjectsAdvanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation., Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine in adults., Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10014743Term: Endometrial carcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10007476Term: Carcinoma thyroid Class: 10029104CTIS2022-501327-25-00Bluepharma Industria Farmaceutica S.A.36
招募中
1 期
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditionso medical condition.CTIS2024-513753-75-00Bial Portela & Ca S.A.32
进行中（未招募）
1 期
Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.o medical conditionCTIS2023-506416-41-00Tecnimede-Sociedade Tecnico-Medicinal S.A.16
进行中（未招募）
1 期
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.CTIS2023-508339-29-00Bluepharma Industria Farmaceutica S.A.12